

To: Prospective Applicants

From: Valerie Mojeiko, Deputy Director, Multidisciplinary Association for Psychedelic Studies

Date: December 17, 2010

Re: Request for Proposal for Ibogaine Clinical Study Grant

**About Grant:** MAPS is offering a grant to a research team who is interested in conducting a clinical study with ibogaine. MAPS will award up to \$25,000 in matching funds to one team who has a plan to secure an additional \$25,000 or who has secured grant monies for this research project in the past 12 months. Only one grant will be awarded.

**Proposal Deadlines and Review Timetable:** All proposals are due on April 1, 2011 at 11:59PM Pacific Time. Please do not fax proposals. A decision will be made and all parties notified by May 31, 2011.

**Eligibility:** Grant will be awarded to a team who has adequate resources and credentials to design and conduct a clinical trial. Team must also be able to navigate local regulatory agencies in order to conduct trial in compliance with all applicable regulations. Team must be willing to keep all data in the public domain and seek publication of results.

**How to Apply:**

Submit electronic copies (PDFs) of the following in a single email to [valerie@maps.org](mailto:valerie@maps.org).

1. Protocol Summary (Not more than 10 pages) with the following sections included:

o. COVER PAGE with Name/Address of Institution where research will be conducted, Names and Credentials of Investigators and all sub-investigators/independent raters that are currently known

1. STUDY AIM, BACKGROUND AND DESIGN

Briefly describe the purpose of this study

2. SUBJECT POPULATION INCLUSION/EXCLUSION CRITERIA

Include Inclusion/Exclusion Criteria, Number of Subjects, and recruitment procedures.

3. BRIEFLY DESCRIBE RESEARCH METHODS OR PROCEDURES TO BE DONE FOR THE PURPOSES OF THE STUDY (example: tests, labwork, surveys, participant observations, etc.)

4. RISKS: POTENTIAL RISKS/DISCOMFORTS TO SUBJECTS AND METHODS OF MINIMIZING THESE RISKS

Any risk to participants is of major concern to the committee. Please detail any possible

psychological or physical risk and methods to minimize them.

5. BENEFITS: POTENTIAL DIRECT BENEFITS TO SUBJECTS AND GENERAL BENEFITS TO SUBJECT GROUPS, ACADEMIC OR PROFESSIONAL DISCIPLINE AND/OR SOCIETY

Any benefit to participants is also of concern to the committee. Please detail any possible

psychological or physical benefit. Benefit may include more than compensation for participating in the study.

6. Indicate NUMBER OF SUBJECTS TO BE ENROLLED in the study.

2. Proposed Budget: Clinical study may cost more than the \$50,000 that would be raised through this grant and associated matching funds. Please account for entire budget for conduct of study and plan for generating income.

3. CV for Principal Investigators and Relevant Core Study Staff (i.e. Principal investigator; nurses, doctors, therapists, or other attendants who will have direct patient contact; independent rater)

**Evaluation Process:** Grant will be awarded by a committee consisting of a team of three reviewers from MAPS. The following factors will be taken into consideration when evaluating proposals (not in order of priority):

\*Credentials of team members and prior experience conducting clinical trials

\*Demonstrated ability of the team to navigate regulatory agencies

\*Plan for fundraising and demonstrated ability to raise funds

\*Sophistication of research design

\*Safety Plan—both medical and psychological

\*Location of proposed trial (all locations considered)

**Contact:** For questions, please contact Valerie Mojeiko, Deputy Director, MAPS, at [Valerie@maps.org](mailto:Valerie@maps.org) or 831-429-6362 ext. 102.

**About MAPS: Our mission is** 1) to treat conditions for which conventional medicines provide limited relief—such as posttraumatic stress disorder (PTSD), pain, drug dependence, anxiety and depression associated with end-of-life issues—by developing psychedelics and marijuana into prescription medicines; 2) to treat many thousands of people by building a network of clinics where treatments can be provided; and 3) to educate the public honestly about the risks and benefits of psychedelics and marijuana.